D.E. Shaw & Co
SYRE icon

D.E. Shaw & Co’s Spyre Therapeutics SYRE Stock Holding History

D.E. Shaw & Co’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-19,056
Closed -$241K – 5512
2022
Q2 		$241K Buy
19,056
+892
+5% +$31.3K ﹤0.01% 4462
2022
Q1 		$1.04M Buy
18,164
+9,064
+100% +$761K ﹤0.01% 3889
2021
Q4 		$1.08M Buy
9,100
+7,960
+698% +$1.26M ﹤0.01% 3862
2021
Q3 		$227K Sell
1,140
-699
-38% -$122K ﹤0.01% 4509
2021
Q2 		$320K Sell
1,839
-671
-27% -$122K ﹤0.01% 4246
2021
Q1 		$497K Sell
2,510
-1,959
-44% -$376K ﹤0.01% 3507
2020
Q4 		$879K Buy
4,469
+699
+19% +$145K ﹤0.01% 3100
2020
Q3 		$669K Buy
3,770
+52
+1% +$9.62K ﹤0.01% 3080
2020
Q2 		$860K Buy
3,718
+2,628
+241% +$501K ﹤0.01% 3032
2020
Q1 		$127K Buy
+1,090
New +$185K ﹤0.01% 3752
2019
Q3 		– Sell
-2,015
Closed -$345K – 4011
2019
Q2 		$345K Buy
2,015
+1,259
+167% +$218K ﹤0.01% 3254
2019
Q1 		$152K Buy
+756
New +$158K ﹤0.01% 3437

Other funds holding SYRE

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

D.E. Shaw & Co's SYRE Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Spyre Therapeutics (SYRE) in Q3 2022, closing a stake of 19,056 shares — an estimated $241K sold.

D.E. Shaw & Co first reported a position in SYRE in Q1 2019 and held it in 12 quarters. The position peaked at $1.08M in Q4 2021. 55 funds tracked by Wall St. Rank hold SYRE as of Q3 2022.

  • D.E. Shaw & Co reported no remaining Spyre Therapeutics position as of Q3 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 19,056 Spyre Therapeutics shares in Q3 2022, an estimated $241K.
  • D.E. Shaw & Co first reported a position in Spyre Therapeutics in Q1 2019 and held it in 12 quarters.
  • D.E. Shaw & Co's Spyre Therapeutics position peaked at $1.08M in Q4 2021.
  • 55 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.